Reproductive Healthcare Reimagined
GenBioPro: A New Vision for Reproductive Health
GenBioPro is changing the landscape for reproductive health. We are a new and different kind of pharmaceutical company, determined to make a difference. Our mission and values are straightforward: We stand for personal dignity, access to medical evidence, self-determination, and a world that ensures that safe, affordable, reproductive health care — including medical abortion — is within reach for everyone.
Attaining fair and equitable access to reproductive health care is our north star and guiding principle.
It informs:
Who We Are
Learn more about our advocacy.
We are dedicated to decreasing barriers, increasing access, and advocating for health care providers, pharmacies, and patients alike. Are you with us?
The Evolving Landscape for Medical Abortion
Progress and Continuing Challenges
The original promise of medical abortion, more than 20 years ago, was that it would revolutionize reproductive health care by breaking down silos and decentralizing abortion care, making it more readily available. This promise has been slow to materialize in the US. For many years, medically unnecessary restrictions and political interference have resulted in medical abortion being inaccessible for far too many people. Limitations on abortion care training, high costs, laws banning abortion care and targeting providers, and disinformation are just some of the barriers that still constrain access to abortion care. Yet despite these obstacles, we continue to move closer to the realization of accessible reproductive health care that is available to all who need it. With recent regulatory changes and the growing participation of prescribers and pharmacies, today medical abortion is better known, more widely available, and used by the majority of people seeking abortion care.
Before GenBioPro, health care providers had limited options for quality, reasonably priced family-planning products that millions of their patients depended on.
GenBioPro Impact: Advocating Access; Accelerating Change
GenBioPro is proud to be a part of improving access to medical abortion care and to helping advance medical research to improve reproductive health. Here are just a few of our contributions:
1980
The abortion pill is developed in France
1988
First approval of the abortion pill in France, spreading to the rest of Europe
1990
.
2000
FDA approves abortion pill for use in the US
2010
.
2012
GenBioPro is founded; begins to advocate for increased access to medical abortion
2016
FDA changed to the label and regulations governing the abortion pill:
- Reduced the dose from 600 to 200 mg
- Expanded the treatment window from 49 to 70 days of the first day of the last menstrual period
- Broadened which providers could prescribe
- Reduced the number of required follow-up visits from two to one
2019
GenBioPro obtains FDA approval for a generic abortion pill for use in the US, which:
- Stimulated price reductions
- Stabilized product supply
- Increased choice and access
2020
.
2021
In response to the COVID19 pandemic and court orders, the FDA temporarily allowed:
- Visits for abortion care to occur remotely rather than in person
- Delivery of medications by mail
2023
GenBioPro advocated for further changes to the label and requirements governing the abortion pill:
- Permanently removed in-person dispensing requirements, allowing telemedicine care in states where it is permitted
- Expanded dispensing options to include filling prescriptions through certified pharmacies, permitting in-store pickup and mailing prescriptions to homes, in addition to in-person dispensing
- Simplified the Prescriber Agreement and made it portable
We remain committed to advocacy to ensure that access to high-quality reproductive healthcare, including medical abortion – is available to all who need it.
Need More Information?
Contact us if you have questions about our products:
Online | 1-855-643-3463 | info@genbiopro.com